You think a lot of upside is priced in at a $200m MC? Based on what metrics? Keen to understand.
I can’t see how a $3b per annum (minimum) market opportunity, with very little to no competition and (if granted) the backing of the FDA to grant early approval, would be valued at approx 3% with a 95-97% discount for risk that close to a green light. It just wouldn’t happen.
an $600m MC would make more sense in P2 IMO.
You think a lot of upside is priced in at a $200m MC? Based on...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 25000 | 1 |
View Market Depth
| Last trade - 16.12pm 08/05/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable